Clinical efficacy of arsenic trioxide combined with carboplatin for neoadjuvant chemotherapy for locally advanced cervical cancer

Phase 4

• Conditions: Cervical cancer

• Registration Number: ITMCTR1900002399
• Lead Sponsor: The First Affiliated Hospital of Guangzhou University of Chinese Medicine

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Last Update Posted: 20 February 2023

Recruitment & Eligibility

• Status: Pending
• Sex: Female
• Target Recruitment: Not specified

Inclusion Criteria

1 Aged 20-60 years;
2 Patients with stage IB2, IIA2, IIB cervical cancer;
3 Normal blood analysis, liver and kidney function before treatment;
4 No evidence of distant metastasis;
5 No serious heart, liver, kidney and blood system and other important organ diseases;
6 Patients have signed the informed consent

Exclusion Criteria

1 Early or small lesions do not require neoadjuvant chemotherapy patients;
2 cachexia:PS score = 3 points, KPS score < 70 points;
3 Active infection or bleeding;
4 Complete intestinal obstruction;
5 Uncontrolled psychosis;
6 Pregnant and lactating women;
7 Allergic constitution, or known to arsenic allergy patients;
8 Late no possibility of surgery patients;
9 Patients who are unwilling to receive neoadjuvant chemotherapy combined with surgery in the advanced stage;
10 Patients with severe comorbidities;
11 Patients who cannot tolerate chemotherapy and surgical words; 13 Patients who have participated in other clinical trials in the last 3 months;
12 Any other conditions that the investigator considers unsuitable for participation in this trial.

Study & Design

• Study Type: Interventional study
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
efficiency evaluation;